67 reports

  • KEY BUYING CRITERIA FOR GLOBAL AUTOIMMUNE AND INFLAMMATORY IMMUNOMODULATORS MARKET 2015
  • KEY MARKET HIGHLIGHTS

It causes chronic inflammation of any part or the entire gastrointestinal tract.

  • Cancer Immunotherapy
  • Therapy
  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • CANCER VACCINES MARKET, GLOBAL, PIPELINE FOR THERAPEUTIC VACCINES BY INDICATION AND MOLECULAR
  • CANCER VACCINES MARKET, GLOBAL, APPROVED INDICATIONS FOR CERVARIX, 2016

Dietary factors have a substantial influence on the risk of cancers of the gastrointestinal tract.

  • Cancer
  • Cancer Immunotherapy
  • Cell Therapy
  • Therapy
  • Vaccine

Advances in the treatment of gastrointestinal stromal tumours.

  • Cancer Immunotherapy
  • World
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Pfizer Inc.

PD-## does this by attaching itself to PDL-##, a protein present on healthy cells in the body.

  • Cancer Immunotherapy
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.

Gastrointestinal Cancers Symposium for Taiho Oncology’s Lonsurf (trifluridine and tipiracil); views on new data announced from the Phase II CheckMate-## trial evaluating Opdivo (nivolumab; Merck & Co. ) and Yervoy (ipilimumab; BMS) for the treatment of patients with DNA mismatch repair

  • Cancer Immunotherapy
  • Colorectal Cancer
  • Monoclonal Antibody
  • Oncology
  • Therapy

The auto exports exceeded over ## million each year.

  • Cancer Immunotherapy
  • Renal Cancer
  • Therapy
  • China
  • Bayer Schering Pharmaceutical Co., Ltd

Aduro announced the promising initial results from the first Phase ## trial of this combination therapy at the American Society of Clinical Oncology (ASCO) 2014 Gastrointestinal Cancers Symposium.

  • Cancer Immunotherapy
  • World
  • Altor BioScience Corporation
  • GlobeImmune, Inc.
  • Merck & Co., Inc.

WHEN ADMINISTERED AS A SINGLE AGENT, OTHER COMMON COMPLAINTS BESIDES SKIN TOXICITIES INCLUDED FATIGUE, FEVER, GENERAL PAIN, AND VARIOUS GASTROINTESTINAL (GI) DISTURBANCES (ERBITUX PACKAGE INSERT, 2015).

  • Cancer
  • Cancer Immunotherapy
  • Chemotherapy
  • Hospital
  • Therapy
  • Pipeline Landscape Assessment

Other symptoms include retrosternal pain, weight loss, hematemesis (vomiting blood) and melena (black feces associated with gastrointestinal hemorrhage).

  • Cancer Immunotherapy
  • World
  • Market Size
  • Celgene Corporation
  • Merck & Co., Inc.

Cervarix users report fatigue, headache, myalgia, gastrointestinal problems, and arthralgia after vaccination.

  • Cancer Immunotherapy
  • World
  • Dendreon Corporation
  • GlaxoSmithKline plc
  • Merck & Co., Inc.

THE MOLECULES THAT BLOCK PD-## PATHWAY INHIBIT THE INTERACTION BETWEEN PD- ## AND ITS LIGANDS (PDL-## AND PDL-##).

  • Cancer Immunotherapy
  • North America
  • United States
  • Incyte Corporation
  • Merck & Co., Inc.
  • AT THE 2017 GASTROINTESTINAL CANCERS SYMPOSIUM IN SAN FRANCISCO, CALIFORNIA.
  • Phase I/II - Trial Details

Leiomyosarcoma - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma - Pipeline Review, H1 2018, provides an overview of the Leiomyosarcoma (Oncology) pipeline landscape. Leiomyosarcoma is an aggressive soft tissue...

  • Cancer Immunotherapy
  • Hospital
  • Lung Cancer
  • Therapy
  • Merck & Co., Inc.

Our Phase ## clinical trial is expected to start later in 2018. "

  • Cancer Immunotherapy
  • Healthcare
  • Pharmaceutical
  • United States
  • Compugen Ltd.
  • DORMANT PRODUCTS, H1 2018 (CONTD..1), H1 2018
  • TREMELIMUMAB - DRUG PROFILE

Waxman, M. D., development lead, Gastrointestinal Cancers, Bristol-Myers Squibb.

  • Biotech
  • Cancer Immunotherapy
  • Monoclonal Antibody
  • Oncology
  • Therapy
  • AT THE 2017 GASTROINTESTINAL CANCERS SYMPOSIUM IN SAN FRANCISCO, CALIFORNIA.
  • ADVANCED MALIGNANCIES. THE TRIAL WAS REGISTERED WITH THE U.S. NATIONAL INSTITUTES OF HEALTH.

Nasopharyngeal Cancer - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer - Pipeline Review, H1 2018, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape. Nasopharyngeal cancer...

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • United States
  • Product Initiative
  • AT THE 2017 GASTROINTESTINAL CANCERS SYMPOSIUM IN SAN FRANCISCO, CALIFORNIA.
  • IPILIMUMAB + NIVOLUMAB - DRUG PROFILE

Osteosarcoma - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H1 2018, provides an overview of the Osteosarcoma (Oncology) pipeline landscape. Osteosarcoma is the most common cancer of the...

  • Cancer
  • Cancer Immunotherapy
  • Hospital
  • Targeted Therapy
  • Therapy
  • 2017 GASTROINTESTINAL CANCERS SYMPOSIUM IN SAN FRANCISCO, CALIFORNIA.
  • NIVOLUMAB - DRUG PROFILE

Sepsis - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Sepsis - Pipeline Review, H1 2018, provides an overview of the Sepsis (Infectious Disease) pipeline landscape. Sepsis is an illness in which the body has a severe response...

  • Blood Disease
  • Cancer Immunotherapy
  • Respiratory Disease
  • Therapy
  • Bristol-Myers Squibb Company
  • REGISTERED WITH THE U.S. NATIONAL INSTITUTES OF HEALTH.
  • UNITED STATES. DEPENDING ON THE RESULTS OBSERVED, FURTHER DEVELOPMENT OF THE COMBINATION MAY BE WARRANTED.

Gastrointestinal TEAEs were in line with historic IR-v data.

  • Cancer Immunotherapy
  • Hospital
  • Lung Cancer
  • Pharmaceutical
  • Therapy

The Company is preparing to initiate one of the Phase ## trials at one of the world' s leading university hospital networks located in the Northeast U. S.

  • Cancer Immunotherapy
  • Cytokine
  • Hospital
  • Vaccine
  • Product Initiative
  • DORMANT PRODUCTS, H2 2017 (CONTD..1), H2 2017
  • TREMELIMUMAB - DRUG PROFILE

Waxman, M. D., development lead, Gastrointestinal Cancers, Bristol-Myers Squibb.

  • Cancer
  • Cancer Immunotherapy
  • Monoclonal Antibody
  • Oncology
  • Therapy
  • with the U.S. National Institutes of Health.
  • Licensing and Collaboration

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Cancer Immunotherapy
  • Lung Cancer
  • Targeted Therapy
  • Therapy
  • Bristol-Myers Squibb Company
  • presented, at the 2016 European Society for Medical Oncology (ESMO) Congress during an oral proffered paper session.
  • Research and Development Brief

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Cancer Immunotherapy
  • Chemotherapy
  • Lung Cancer
  • Pharmaceutical
  • Therapy

Results from the Phase I study were presented at the 2017 Gastrointestinal Cancers Symposium. ## G/ GEJ pts have been enrolled in the study.

  • Cancer
  • Cancer Immunotherapy
  • Lung Cancer
  • Therapy
  • Merck & Co., Inc.
  • JUN 05, 2016: NIVOLUMAB SHOWS PROMISE IN FIRST-EVER TRIAL FOR PATIENTS WITH REFRACTORY, METASTATIC ANAL CANCER
  • JUN 05, 2016: NIVOLUMAB SHOWS PROMISE IN FIRST-EVER TRIAL FOR PATIENTS WITH REFRACTORY, METASTATIC ANAL CANCER

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • United States
  • Product Initiative
  • JUN 05, 2016: NIVOLUMAB SHOWS PROMISE IN FIRST-EVER TRIAL FOR PATIENTS WITH REFRACTORY, METASTATIC ANAL CANCER
  • presented, at the 2016 European Society for Medical Oncology (ESMO) Congress during an oral proffered paper session.

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • United States
  • Product Initiative
  • 08/11/2017: FDA Approves Updated Indication for Opdivo (nivolumab)

Boku Abstract ##O Proffered Paper Session: Gastrointestinal Tumors, Non-Colorectal ## Friday, September ##, ##:##-##:## PM CEST, Barcelona Auditorium Author: Y.

  • Cancer Immunotherapy
  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • Ono Pharmaceutical Co., Ltd.

AS OF FEBRUARY 2013, IT WAS IN PHASE II FOR GASTROINTESTINAL STROMAL TUMOR (GIST).

  • Cancer Immunotherapy
  • Hospital
  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • NIVOLUMAB - DRUG PROFILE

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • United States
  • Product Initiative
  • NIVOLUMAB - DRUG PROFILE

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Cancer Immunotherapy
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • LIST OF ABBREVIATIONS

August 2016 Development ## ##. ##. ## A P P R O V A L S February 2016 F.

  • Cancer Immunotherapy
  • Oncology
  • North America
  • United States
  • Market Size